ARM T-CellTM Platform

Targeting tumors with precision.

Close-up illustration of engineered T-cells binding to cancer cells.

Hematological Focus

Our ARM T-cell technology is designed to attack blood cancers effectively, offering hope to patients with diverse genetic backgrounds and ages, including non-responders to current treatment.

Microscopic view of blood cells with highlighted cancer cells targeted by immunotherapy.

Solid Tumors

We extend our immunotherapy approach to solid tumors, aiming for long-lasting treatment effects across various cancer types.

About Animus Biopharma

We develop next-gen in vivo T cell immunotherapy targeting both blood cancers and solid tumors.

Our Technology

Collaboration

Our ARM T-cell tech targets tumors long-term and suits all genetic backgrounds and ages.